News & readouts · Updated weekly
A running log of every meaningful retatrutide development — trial readouts, regulatory updates, scientific publications, and corporate news from Eli Lilly. Sorted newest first.
On its Q1 2026 earnings call, Eli Lilly reaffirmed prior guidance that the first TRIUMPH topline readout is expected during 2026, with no change to enrollment status.
Source: Eli Lilly Q1 2026 earnings call
Sell-side coverage refined estimates for the cardiovascular-outcomes-relevant TRIUMPH-3 trial, citing event-rate pacing in the trial's interim adjudication.
At its February 2026 investor day, Lilly outlined commercial readiness for a retatrutide launch, including manufacturing capacity expansion at its Indiana and North Carolina sites.
Presentation at ObesityWeek 2025 included extended follow-up data from the Phase 2 obesity trial, with weight-loss curves continuing to trend downward in extension cohorts.
Lilly confirmed that all four TRIUMPH-program pivotal trials — TRIUMPH-1 through TRIUMPH-4 — have completed enrollment, setting the stage for sequential 2026 readouts.
Rosenstock et al. published Phase 2 type 2 diabetes results in The Lancet, demonstrating ~2.0 percentage point HbA1c reductions and ~17% weight loss at 36 weeks at the highest dose.
Source: The Lancet ↗
Jastreboff et al. published the Phase 2 obesity trial results in the New England Journal of Medicine. The 12 mg dose produced an average 24.2% weight loss at 48 weeks.
Source: N Engl J Med ↗
Coskun et al. published the discovery and Phase 1 proof-of-concept paper for LY3437943 in Cell Metabolism, establishing the molecule's triple-receptor pharmacology.
Source: Cell Metabolism ↗
Stay informed
Plain-language summaries of every major trial readout, label development, and approval milestone — no spam.
Continue exploring
Triple agonism of GLP-1, GIP, and glucagon receptors — and why activating all three matters.
Read →TRIUMPH-1 through TRIUMPH-4: design, primary endpoints, and reported readouts.
Read →Phase 2 obesity outcomes by dose, BMI subgroup, and time on therapy.
Read →